BTG (BTG) Receives Underperform Rating from Royal Bank of Canada
BTG (LON:BTG)‘s stock had its “underperform” rating reiterated by equities researchers at Royal Bank of Canada in a report issued on Tuesday.
A number of other equities analysts also recently commented on the company. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of BTG in a research report on Friday, October 5th. Shore Capital restated a “buy” rating on shares of BTG in a research report on Thursday, August 9th. Deutsche Bank restated a “hold” rating and issued a GBX 645 ($8.43) target price on shares of BTG in a research report on Monday, September 24th. Peel Hunt restated a “hold” rating on shares of BTG in a research report on Tuesday, September 4th. Finally, Numis Securities restated a “buy” rating on shares of BTG in a research report on Friday, September 7th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of GBX 704.17 ($9.20).
Shares of BTG stock opened at GBX 830.10 ($10.85) on Tuesday. BTG has a one year low of GBX 559.82 ($7.32) and a one year high of GBX 784 ($10.24).
BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, and internationally. It operates through three segments: Interventional Medicine, Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications.
Featured Story: Asset Allocation and Your Retirement
Receive News & Ratings for BTG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG and related companies with MarketBeat.com's FREE daily email newsletter.